TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06789913: A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReIns

Sponsor: Relay Therapeutics, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 277 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,556,400

Rescue Site Savings

+$1,693,200

Unlock Full NCT06789913 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06789913 Rescue Dossier →